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Abstract
Background The technique of 5-aminolevulinic acid (5-ALA)
tumor fluorescence is increasingly used to improve visualiza-
tion of tumor tissue and thereby to increase the rate of patients
with gross total resections. In this study, we measured the
resection volumes in patients who underwent 5-ALA-guided
surgery for non-eloquent glioblastoma and compared them
with the preoperative tumor volume.
Methods We selected 13 patients who had received a com-
plete resection according to intraoperative 5-ALA induced
fluorescence and CRET according to post-operative T1
contrast-enhanced MRI. The volumes of pre-operative con-
trast enhancing tissue, post-operative resection cavity and
resected tissue were determined through shift-corrected volu-
metric analysis.
Results The mean resection cavity (29 cm3) was marginally
smaller than the pre-operative contrast-enhancing tumor
(39 cm3, p =0.32). However, the mean overall resection vol-
ume (84 cm3) was significantly larger than the pre-operative
contrast-enhancing tumor (39 cm3, p =0.0087). This yields a
mean volume of resected 5-ALA positive, but radiological
non-enhancing tissue of 45 cm3. The mean calculated rim of
resected tissue surpassed pre-operative tumor diameter by
6 mm (range 0–10 mm).
Conclusions Results of the current study imply that (i) the
resection cavity underestimates the volume of resected tissue
and (ii) 5-ALA complete resections go significantly beyond
the volume of pre-operative contrast-enhancing tumor bulk on
MRI, indicating that 5-ALA also stains MRI non-enhancing
tumor tissue. Use of 5-ALA may thus enable extension of
coalescent tumor resection beyond radiologically evident tu-
mor. The impact of this more extended resection method on
time to progression and overall survival has not been deter-
mined, and potentially puts adjacent and functionally intact
tissue at risk.
Keywords 5-ALA .CRET .Complete resection of enhancing
tumor . Extent of resection . Glioblastoma
Introduction
Although they are solid tumors, glioblastomas are not well
delineated and the boundaries are often difficult to discern
during white-light surgery. Cell density decreases gradually
from the solid tumor tissue towards the infiltrative tumor
periphery. The compound 5-aminolevulinic acid (5-ALA) is
a technical adjunct that—when given orally before surgery—
accumulates in glioma cells as a fluorescent metabolite and
thereby improves both the intraoperative detection of tumor
tissue and the extent of resection. The use of 5-ALA as a
method of intraoperative imaging has become increasingly
popular since a randomized controlled trial showed that the
likelihood of achieving a gross total resection (GTR) in-
creased significantly when using 5-ALA induced fluorescence
compared to white light only (65 % vs 37 %; p <0.0001) [11].
Fluorescence of 5-ALA is thought to depend not only on the
degree of blood–brain barrier disruption, but also on a variety
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of factors such as an increased cellular metabolism and a
modified tumor microenvironment [3].
Gadolinium-enhanced T1-weighted MR sequences—
the modality of choice to detect solid tumor outside of
surgery—detects the tumor’s disrupted blood–brain bar-
rier [2]. Thus, T1 enhanced magnetic resonance imaging
(MRI) and intra-operative 5-ALA imaging identify different
characteristics of a tumor, and may depict a different extent of
tumor in a given patient. While the ability of 5-ALA guided
surgery to resect at least the contrast enhancing tumor part
(i.e. GTR) is undisputed after the 5-ALA study [11], it remains
unclear to what extent the use of 5-ALA leads to tissue
resection beyond contrast enhancement.
It is of great clinical importance for the planning of surgery
to know if, and to what extent, 5-ALA fluorescence visualizes
tumor tissue beyond the gadolinium-enhancing rim on preop-
erative MRI, as larger resections may endanger nearby elo-
quent areas. In addition, it may be of conceptual significance
to know if 5-ALA guides towards a more complete tumor
resection than indicated by a T1-contrast MRI.
The aim of our study was to compare the volume of
contrast enhancing tumor as seen on pre-operative T1-
contrast MRI with the resection volume on the post-
operative T1 MRI after 5-ALA-guided surgery for non-
eloquent glioblastoma.
Methods
Study protocol and inclusion criteria
Data regarding presenting symptoms, Karnofsky Performance
Scale, perioperative morbidity and mortality were retrieved
from our departmental prospective glioma register. The regis-
ter included results of complete clinical and neurological
examinations performed on the day before surgery, at dis-
charge, and 6 to 8 weeks after surgery. All patients were
operated upon according to our institutional protocol which
stipulates that glioblastoma resection in presumed non-
eloquent areas should progress according to fluorescence until
complete removal of all fluorescent tissue (both solid and
vague fluorescence). Pre- and postoperative neurologic defi-
cits were recorded, in addition to any changes in the degree of
deficits over time. All 102 patients who underwent surgery for
glioblastoma from 1 August 2008 to 30 July 2010 at the
Department of Neurosurgery, Bern University Hospital,
Bern, Switzerland, were screened for this study. Pre-
operative MRI not older than 7 days at the time of surgery
and complete resection of enhancing tissue (CRET) on early
post-operative T1-contrast MRI were prerequisites for study
inclusion. For methodological reasons related to the shift
corrected volumetric analysis we selected 13 patients with a
spherical, non-multifocal contrast enhanced tumor with a
volume larger than 10 cm3 and located close to the brain
surface in a non-eloquent area. All patients signed a surgical
consent form. The local Ethics committee approved the study
(Cantonal Ethics Commission Bern, 10-8-2010).
Imaging protocol
Specifications of pre- and post-operative MRI were identical:
AllMRIs were performed on a 1.5 or a 3 Tscanner with a head
coil. Unenhanced and enhanced T1 sequences without gap
were obtained (magnetized-prepared rapid-acquisition gradi-
ent echo [MP-RAGE] sequences with 0.1 mmol/kg
bodyweight gadolinium-diethylenetriaminepentaacetic acid
[DTPA] given intravenously, 256×256 matrix, rectangular
field of view, slice thickness 1 mm). Post-operative MRI
was obtained within 48 h after surgery.
5-ALA and surgery protocol
All patients received 4 mg of dexamethasone three times a day
for at least 3 days prior to surgery (with the exception of
patient 5, who received steroids only during surgery). 5-
ALA (20 mg/kg body-weight) was diluted in 50 mL of water
and given orally 3 h before the induction of anesthesia (range
2–4 h). All patients received mannitol (20 %, 250 ml) at the
beginning of surgery. Surgery was carried out with the use of a
neurosurgical microscope (OPMI Pentero, Carl Zeiss)
equipped with the fluorescence kit. Blue light was used for
identification of tumor tissue at several stages of surgery.
Surgery was performed according to fluorescence with the
aim to remove all fluorescent (solid and vague) tissue while
sparing non-fluorescent parenchyma. Central necrosis was
resected regardless of fluorescence. At the end of surgery,
the resection cavity was again checked with blue light to
ensure completeness of tumor removal. Neuronavigation
was performed in all cases for localization control.
Processing of image data
Imaging data from pre- and post-operative MRI were uploaded
into Brainlab® iPlan 3.0.2 cranial software (VectorVision,
Brainlab, Heimstetten, Germany). Volumetric analysis was
performed through manual segmentation across all slices
(volume 1) or manually corrected autosegmentation (volumes
2 and 3) [6]. All volumetric assessments were performed on
gadolinium-enhanced T1 sequences (MP-RAGE). The follow-
ing volumes were obtained:
1. Pre-operative tumor volume: All tissue with pathological
enhancement on pre-operative gadolinium-enhanced T1
sequences; plus central necrosis
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2. Volume of the resection cavity: Cavity at the former tumor
site, including debris and blood, as seen on post-operative
gadolinium-enhanced T1 sequences
3. Pre- and post-operative brain volume: The autosegmentation
feature of the iPlan software was used to obtain the
cerebral volume (supratentorial brain volume with-
out CSF spaces and tumor). Using anatomical atlas
information for initialization, this feature is based on
an expectation-maximization algorithm under specif-
ic statistical assumptions on the gray value distribu-
tion of brain tissue classes [14]. A manual slice per
slice correction ensured optimized accuracy.
4. The volume of resected tissue that did not enhance in the
pre-operative MRI was obtained with the formula:
Volume of resected non‐enhancing tissue ¼
Preoperative Brain volume−Postoperative Brain volume
5. The overall volume of resected tissue is the sum of en-
hancing and non-enhancing resected tissue:
Overall resection volume ¼
Tumor volumeþ volume of resected non‐enhancing tissue
6. Additional 5-ALA resection margin calculation
The mean tumor diameter is calculated using tumor
volume (we postulate a spherical resection, analogous
to the pre-operative spherical tumor shape [inclusion
criterion]). The diameter of the resected tissue is calcu-
lated accordingly.
Standard deviations for calculated quantities (tumor diam-
eter, volume of resected unenhancing tissue, overall resection
volume, total resected tissue diameter, volume of resection
cavity in percentage of pre-op enhancing tumor, volume of
resected tissue in percentage of pre-op enhancing tumor, mean
resected rim beyond contrast enhancement) were estimated
according to the rules of error propagation [5].
Results
Demographics and tumor volume
Mean age at surgery was 61 years (range 48–80 years), and 6
of the 13 patients were women. Steroids were given for a
mean duration of 6 days prior to imaging (range 0–16 days)
and 3.5 days prior to surgery (range 0–15 days). All pre-
operative MRIs were not older than 1 week at the time of
surgery. Mean pre-operative tumor volume (contrast enhance-
ment on gadolinium-enhanced T1 sequences plus necrosis)
was 39 cm3 (range 11–93 cm3). Intra-operative electrophysi-
ologic mapping and monitoring was used in three patients as a
safety measure due to the tumor’s proximity to cortical and
subcortical motor areas: Somatosensory evoked potentials
(SSEP), trans-epidermal stimulation motor evoked potentials
(TES MEP) and cortical motor mapping in patient 2; SSEP,
TES MEP and direct cortical stimulation MEP (DCSMEP) in
patients 10 and 13. Monitoring signals were stable in all
patients and thus did not lead to early termination of resection.
Volume of the resection cavity
The resection cavity without any shift correction had a mean
volume of 29 cm3 (range 6–80 cm3) according to the post-
operative T1 MRI (Table 1) and was thus marginally smaller
than the pre-operative contrast enhancement (unpaired t -test,
95 % confidence interval −30.3 to 10.4, two-tailed P=0.32),
although no contrast enhancing remnant was seen on the post-
operative gadolinium-enhanced MRI (all patients had GTR).
For individual patients, the resection cavities’ relative size
compared to the preoperative tumor ranged from 22 % to
192 % (Table 1).
Pre- and post-operative brain volume, and volume of resected
non-enhancing tissue
The mean pre-operative brain volume (supratentorial brain
without enhancing tumor, central necrosis) was 1,077 cm3
(range 967–1,253 cm3). The early post-operativeMRI showed
a mean brain volume of 1,032 cm3 (range 870–1,199 cm3).
The mean volume of resected tissue that did not enhance on
gadolinium-enhanced pre-operative MRI was calculated to be
46 cm3 (range 1–120 cm3).
Overall volume of resected tissue
The overall resection volume, encompassing enhancing and
non-enhancing tissue, correlated well with the volume of GD
enhancing tumor on pre-operative MRI (Fig. 1). Overall re-
section volume was 84 cm3 (range of 15–191 cm3) and thus
significantly larger than the mean pre-operative T1-contrast-
enhancing tumor volume of 39 cm3 (unpaired t-test, 95 % CI
8.6 to 80.9, one-tailed P=0.0087). In fact, the mean relative
size of the overall resection volume compared to pre-operative
tumor volume was 242 % (range 101–494 %, Table 1).
Additional 5-ALA resection margin calculation
Comparing the volume-derived diameter of the pre-operative
tumor (mean 4.0 cm, range 2.7–5.6 cm) and of resected tissue
(mean 5.2 cm, range 3.1–7.1 cm), the resection using 5-ALA
yielded a mean additional rim or resection margin of 6 mm
that was removed beyond the T1 contrast enhancement border
(range 0–10 mm).
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Neurologic deficits
Six patients presented with minor neurological deficits prior to
surgery, of which two improved after administration of ste-
roids and surgery. Postoperatively, we observed no new or
worsened neurologic deficits in the 13 included patients. No
intracranial infection, infarction or hydrocephalus was ob-
served within 3 months after surgery.
Discussion
Evaluation of shift corrected volumetry
Logic implies that after radiological CRET the resection cavity
must be at least the size of the preoperative contrast enhance-
ment. However, on early post-operative MRI we observed
resection cavities that were smaller than the preoperative
contrast-enhancing tumor in 9 of 13 patients due to shifting
of the previously dislocated surrounding brain tissue into the
resection cavity following tumor removal (Table 1, Fig. 2). The
resection cavity’s volume thus turned out to be an imprecise
surrogate parameter for the amount of resected tissue in our
series. The problem of brain shift may be bypassed when the
volume of resected tissue is calculated by comparing pre- and
post-operative cerebral volume.
True resection volumes and methodological limitations
Volumetric assessment of pre- and post-operative brain vol-
umes suggest that the volume of resected tissue was more than
twice the volume of gadolinium-enhancing tissue on pre-
operative imaging (+111 %). Methodological limitations have
to be considered because our measurements are essentially
indirect. The discrepancy between contrast-enhancing tumor
volume and volume of resected tissue is unlikely to be due to
tumor growth, as none of the pre-operative MRI scans were
older than 7 days. In addition, brain edema and the resolution
thereof after surgery may have influenced our results, despite
the fact that the patients were under corticosteroid treatment
during the perioperative period. Another possible source of
error may be resection of non-fluorescent tissue in the ap-
proach corridor. However, resection of non-fluorescent tissue
during corticotomy was minimal in these cases specifically
selected for tumor localization close to the brain’s surface.
Thus, we believe that the discrepancy between the pre-
operative enhancing tumor and the volume of resected tumor
is due to the different sensitivities of gadolinium and 5-ALA
in depicting tumor tissue (Fig. 3). However, some limitations
of our methodology have to be considered, as various factors
may influence outcome of our indirect measurements.
Sensitivity and specificity of 5-ALA induced fluorescence
A post-hoc analysis of the 5-ALA randomized controlled trial
with 322 patients revealed that 34 % of patients in whom
surgery was terminated despite residual tumor had a complete
resection according to post-operative MRI [12]. This ques-
tions the sensitivity of gadolinium-enhanced MRI in identify-
ing residual coalescent tumor tissue. In a prospective series of
52 patients, 35 (67 %) showed residual 5-ALA fluorescence
(23 solid and 12 vague fluorescence) at the end of resection,
but only 19 (37 %) patients had remaining contrast enhance-
ment on the postoperative T1-contrast MRI [10]. The same
study also confirmed the high specificity of 5-ALA induced
fluorescence, as all but one of 212 serial biopsies of fluores-
cent tissue contained tumor cells. These findings imply
that the resection of all fluorescent tissue (5-ALA complete
Fig. 1 Correlation between the
volume of contrast enhancement
on pre-operative MRI and the
overall resection volume.
Pearson’s correlation coefficient:
0.8676 (95 % CI 0.6066–0.9598).
p =0.0001215
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resections) should lead to resection volumes greater than the
preoperative contrast enhancement on the T1 MRI. Our own
results are in line with this assumption.
Diameter of resected tissue: implication for surgical planning
It is of practical importance to know how far 5-ALA fluores-
cence extends beyond the enhancing tumor seen onMRI. The
comparison of calculated mean diameter of preoperative tu-
mor and of resected tissue volume shows that a rim with a
mean width of 6 mm (range 0–10 mm) was resected beyond
contrast enhancement (Table 1). Of course, this 5-ALA-
positive/gadolinium-negative rim may not be homogenous
in all directions as glioma cells are known to migrate along-
side white matter tracts [4, 7]. However, as a rule of thumb, we
believe that a rim of 1 cm around the enhancing tumor should
be regarded as tissue at risk of being resected in 5-ALA guided
surgery.
Risks of 5-ALA guided surgery
Surgery guided by 5-ALA has been shown to carry additional
risks of neurological deficits compared to white light only
[13]. Our own data show that 5-ALA complete resections go
beyond the contrast enhancing tissue on MRI T1 sequences,
therefore involving tissue which might have been regarded
as mainly non-tumoral, functioning brain tissue prior to
surgery. The risk of removing functional brain tissue and
therefore inflicting neurological deficits might increase when
attempting 5-ALA complete resections, as the likelihood of
infiltrated brain tissue instead of coalescent tumor is higher in
the peripheral vaguely fluorescent area compared to areas of
solid fluorescence (88 % versus 46 %, p =0.0136) [10]. No
neurologic deficits were observed in our series, but we only
included tumors in non-eloquent locations and had just 3
tumors within 1 cm from the primary motor cortex and the
corticospinal tract. However, the devoted use of different
available safety enhancing surgical adjuncts such as cortical
Fig. 3 Gadolinium-enhanced
T1-weighted MR sequences of
patient 2. The resection cavity
(right side, post-operative)
appears smaller than the pre-
operative contrast-enhancing
tumor (left side) after 5 ALA—
guided surgery due to shift of the
surrounding brain parenchyma
into the resection cavity
Fig. 2 Gadolinium-enhanced
T1-weighted MR sequences of
patient 9. The resection cavity
(right side, post-operative)
appears larger than the pre-
operative contrast-enhancing
tumor (left side) after 5 ALA—
guided surgery
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and subcortical mapping, MEP monitoring and speech mon-
itoring in awake settings help to identify the essential func-
tional boundaries and thus contribute to the goal of maximiz-
ing tumor resection while keeping postoperative deficits at an
acceptable level [8, 9]. According to the mentioned rule of
thumb, we believe that a 1-cm rim around the enhancing
tumor should be included when assessing the eloquency of a
tumor localization, prompting the use of safety enhancing
surgical adjuncts depending on the eloquent area at risk.
Is there a survival benefit from 5-ALA complete resection
compared to GTR/CRET?
The 5-ALA randomized controlled trial had two important
findings: It showed that the use of 5-ALA leads to an in-
creased rate of GTR (according to postoperative MRI) and
demonstrated in its post hoc analysis an increased overall
survival in patients who received a GTR compared to those
who did not (16.9 versus 11.8 months, p <0.0001) [11, 12].
The same study did not state, however, whether patients had
5-ALA complete resections and it therefore remains yet un-
known whether extending tumor resection beyond contrast
enhancing tissue on MRI has an additional survival benefit
for the patient. Notably, a recent retrospective cohort study
investigated the survival benefit of 5-ALA complete resec-
tions in patients who received CRET. Patients with 5-ALA
complete resection had a significantly longer overall survival
than those with persisting fluorescence at the end of surgery
(27 months versus 17.5 months, p =0.015), despite the fact
that all patients had a complete resection of enhancing tumor
[1]. The potential benefit of 5-ALA complete resections cer-
tainly deserves further investigation and must be weighed
against a possible risk of additional neurological deficits after
extended resections.
Conclusions
In our series, the resection cavity was a surprisingly imprecise
surrogate parameter for the amount of resected tumor tissue
due to post-operative brain shift. We demonstrate by volumet-
ric means that extending glioblastoma resection to a complete
removal of 5-ALA induced fluorescent tumor (5-ALA
complete resection) leads to resection volumes significantly
larger than the volume of contrast-enhancing tumor according
to the preoperative T1-weighted MRI, and thus to resection of
non-gadolinium-enhancing tumor tissue. As a rule of thumb,
5-ALA guided surgery should be used with caution if pre-
operative MRI shows enhancement within 1 cm of eloquent
areas. Given the high specificity of 5-ALA induced fluores-
cence for detecting tumor tissue we must assume that 5-ALA
guided surgery is more efficient in detecting and guiding
removal of tumor tissue than surgery relying solely on pre-
operative MRI imaging. Even though the use of 5-ALA
guided surgery has been proven to increase the likelihood of
achieving a prognostic advantageous radiologic GTR, the
prognostic impact of a 5-ALA complete resection on survival
has not been evaluated to date. It remains to be seen whether
the known prognostic benefit of 5-ALA guided surgery comes
from its ability to resect tumor beyond contrast enhancement
or solely from increasing the likelihood of performing a ra-
diological GTR.
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Comment
This paper by Schucht et al. addresses an important aspect of fluorescence-
guided resections, which is that the volume of ALA-derived tumor fluo-
rescence during surgery of malignant gliomas markedly surpasses the
volume of Gd-enhancement. The volume of Gd-enhancing tissue has
always been the traditional target tissue in surgery for these diffusely
infiltrating lesions and complete resection of Gd-enhancing tumor is one
of the strongest prognostic indicators. Schucht and co-workers quantified
the volume of fluorescing tissue by subtracting brain volume after surgery
from brain volume prior to surgery, and correcting for CSF spaces.
Nevertheless, this elegant approach has methodological limitations, since
changes in brain blood volume or edema resolutions after resection of the
tumor mass were not quantified and possibly cannot be quantified. Still,
the approximation is probably quite good.
This paper complements recent data from Pamplona (1), in which
Aldave and co-workers demonstrate that patients have better survival if
fluorescing tissue is removed completely rather than leaving fluorescing
tissue behind, even if residual tumor does not show up as GD-
enhancement on the MRI. With this experience in mind, one might
consider redefining the aim of surgery for malignant gliomas to extend
resections to include all fluorescing tissue. Of course, maintaining func-
tionality in patients is of utmost importance, and neurophysiological
monitoring and mapping techniques have become indispensible adjuncts
in the surgical therapy of patients with malignant gliomas when using the
potential afforded by ALA-induced tumor fluorescence.
Walter Stummer
Münster, Germany
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